Savaysa (edoxaban) / Daiichi Sankyo - LARVOL DELTA

Renal function and long-term outcomes in edoxaban-treated patients: A subanalysis from ETNA-AF Europe 4 years follow up (ESC-WCC 2025) - No abstract available

Clinical • Atrial Fibrillation • Cardiovascular

Low-dose edoxaban in patients 80 years and older with atrial fibrillation and dose-reduction criteria: randomized analysis between edoxaban 15 mg and 30 mg (ESC-WCC 2025) - No abstract available

Clinical • Atrial Fibrillation • Cardiovascular

Chronic thromboembolic pulmonary hypertension: alternative anticoagulation with edoxaban to vitamin K antagonists and emerging early diagnostic modality with dynamic chest radiography (ESC-WCC 2025) - "Joint session with the Japanese Circulation Society (JCS)"

Cardiovascular • Pulmonary Embolism

Safety and efficacy of edoxaban monotherapy vs dual antithrombotic therapy in patients with stable coronary artery disease and non-valvular atrial fibrillation: a systematic review and meta-analysis (ESC-WCC 2025) - No abstract available

Monotherapy • Retrospective data • Review • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease

The efficacy and safety of edoxaban compared to warfarin in patients with atrial fibrillation with different clinical phenotypes: a meta-analysis of randomized controlled trials (ESC-WCC 2025) - No abstract available

Retrospective data • Atrial Fibrillation • Cardiovascular

The efficacy of 15mg of edoxaban on long-term outcome after PCI in patients with atrial fibrillation and high bleeding risk (ESC-WCC 2025) - No abstract available

Clinical • Atrial Fibrillation • Cardiovascular

Long-term real-world outcomes of edoxaban in atrial fibrillation patients with and without prior ischaemic stroke: A 4-year follow-up analysis from ETNA-AF Europe (ESC-WCC 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Cardiovascular • Ischemic stroke

Comparative effectiveness of dabigatran, rivaroxaban, and edoxaban on cardiac and renal outcomes in Asian patients with atrial fibrillation: a propensity score-weighted analysis (ESC-WCC 2025) - No abstract available

Clinical • HEOR • Atrial Fibrillation • Cardiovascular

Efficacy and safety of prolonged edoxaban treatment for gastrointestinal cancer patients with isolated distal deep vein thrombosis: insight from the ONCO DVT study (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Thrombosis • Venous Thromboembolism

THE UTILITY OF URINE QUALITATIVE ASSESSMENT FOR DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE (EHA 2025) - "The prescribed DOACs were rivaroxaban (18%), dabigatran (23%), edoxaban (26%), and apixaban (33%). The qualitative analysis of direct oral anticoagulants (DOACs) demonstrated a remarkable 99% concordance with the corresponding quantitative measurements across various clinical monitoring scenarios. This level of agreement underscores the utility of a rapid qualitative assessment tool, the validation of which in emergency conditions would help to enhance medical decision-making in acute care indications."

Clinical • Atrial Fibrillation • Cardiovascular • Hepatology • Liver Failure • Nephrology • Oncology • Renal Disease • Venous Thromboembolism

Direct oral anticoagulants in 67 patients with venous thromboembolism and severe thrombophilia. (ISTH 2025) - "All patients received long-term anticoagulation: 21 patients switched from warfarin to DOAC, and 46 patients were treated with DOACs, as first line therapy.Thirty-nine patients received long-term rivaroxaban (of them, 28 patients with 20 mg daily, 4 patients with reduced 10 mg daily dose, 7 patients treated with 20 mg for 1 year and then long term 10 mg), 10 patients received edoxaban (of them 1 patient treated with 30 mg, and 9 patients with 60 mg daily), and 18 patients received apixaban (of them 9 patents treated with 5 x 2 mg daily , 5 with reduced dose: 2.5 mg twice daily, and 4 with 5 x 2 daily for 1 year and then 2.5 x 2 for long term).One patient presented VTE during treatment with 20 mg rivaroxaban for atrial fibrillation and was then switched to full dose apixaban. We observed 2 cases of minor bleeding (both with 20 mg rivaroxaban): one patient suffered by microhematuria and gingival bleeding, and one patient presented occult blood in the stool with sigmoid..."

Clinical • Atrial Fibrillation • Cardiovascular • Infectious Disease • Metabolic Disorders • Oncology • Respiratory Diseases • Venous Thromboembolism

Artificial Intelligence Augmented Decision-Making approach for anticoagulant management (ISTH 2025) - "Among them, 4 patients were on warfarin, 10 patients were on rivaroxaban, and 28 patients took edoxaban. Two patients reported limb pain or swelling on anticoagulants. Table or Figure Upload"

Cardiovascular • Hematological Disorders • Musculoskeletal Pain • Pain • Respiratory Diseases • Venous Thromboembolism

Investigating the effects of anticoagulants on a FVIIa-Antithrombin complex assay (ISTH 2025) - "Methods Different dilutions of the anticoagulants – dabigatran, edoxaban, rivaroxaban, apixaban and unfractionated heparin (INHIBIREF X9222-K, Haematex) were used to spike normal plasma samples (Cryocheck™ normal plasma, Precision Biologics). Warfarinised samples demonstrated reduced level of FVIIa:AT complex by FVIIa-AT assay with slightly reduced FVIIIa:AT complex in the presence of all the other anticoagulants (Table 1). Table or Figure Upload"

Hematological Disorders

VMX-C001 bypasses the effects of FXa-direct oral anticoagulants in healthy adults: ROTEM analysis (ISTH 2025) - "Additionally, older adults (50–79 years) received FXa-DOACs (rivaroxaban, apixaban, edoxaban) for 3.5 days, followed by a single VMX-C001 dose (89–226 mg) or placebo (days 1–4). Results were consistent across groups and VMX-C001 doses. Table or Figure Upload"

Clinical

Management of chronic disseminated intravascular coagulation in small abdominal aortic aneurysm (ISTH 2025) - "Results After 9 days of treatment with intermediate-dose enoxaparin, tranexamic acid, the patient’s platelet count improved significantly to 196,000/mcL, with fibrinogen levels normalizing to 274.2 mg/dL and D-dimer decreasing to 284 ng/mL...Following stabilization, enoxaparin was transitioned to edoxaban (30 mg/day) for long-term management...At her last follow-up, she was asymptomatic, with a platelet count of 268,000/mcL, normalized coagulogram, and fibrinogen level of 130 mg/dL, indicating sustained control of chronic DIC. Table or Figure Upload"

Cardiovascular • Dyslipidemia • Hypotension • Infectious Disease • Metabolic Disorders • Mood Disorders • Oncology • Septic Shock • Thrombocytopenia • Thrombosis

Atypical site vein thrombosis: a five years followup of two centres experience (ISTH 2025) - "All patients performed a Total body CT-Scan and endoscopy was done in 5/9 patients no solid tumors emerged. 5/11 were prescribed apixaban, the others received edoxaban."

Anemia • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Gynecology • Hematological Disorders • Hepatology • Infectious Disease • Oncology • Solid Tumor • Thrombosis • Venous Thromboembolism • JAK2

Rationale for direct oral anticoagulants use in unusual site venous thromboembolism: the DUST study (ISTH 2025) - P=N/A | "Proven efficacy was mentioned in 41.9% of dabigatran prescriptions (vs 12.0% rivaroxaban, 6.0% apixaban, 0% edoxaban, all p<0.001); favorable safety profile in 44.0% of apixaban (vs 17.0% rivaroxaban, p<0.001); expected higher patient adherence in 21.0% of rivaroxaban (vs 7.7% apixaban, p=0.001); availability of an antidote in 14.0% of dabigatran (vs 1.1% apixaban, 0% rivaroxaban, both p=0.001). Table or Figure Upload"

Cardiovascular • Hematological Disorders • Venous Thromboembolism

Smart technology facilitated patient-centered venous thromboembolism management (ISTH 2025) - "The number of patients for the anticoagulant drugs Edoxaban, Rivaroxaban, Warfarin, and Low Molecular Weight Heparin were 28(65.1%), 10(23.3%), 4(9.3%), and 1(2.3%), respectively. The mVTEA has been a great platform for patients to manage themselves and study some relevant knowledge about VTE . Table or Figure Upload"

Clinical • Cardiovascular • Hematological Disorders • Pain • Venous Thromboembolism

The epidemiology of major gastrointestinal bleeding: A national cohort study (ISTH 2025) - "Anticoagulation with direct oral anticoagulants (DOAC), e.g. rivaroxaban, edoxaban and apixaban, has become the dominant therapy. Upper GIB had a higher case fatality rate at all-time compared to lower GIB (7.3% vs 6.5%). Table or Figure Upload"

Clinical • Atrial Fibrillation • Cardiovascular • CNS Disorders • Gastroenterology • Heart Failure • Venous Thromboembolism

The win-ratio for evaluating treatment of cancer-associated VTE: insights from Hokusai VTE Cancer (ISTH 2025) - "Aims To evaluate outcomes in the Hokusai VTE Cancer trial using the win-ratio approach Background The Hokusai VTE Cancer trial demonstrated that edoxaban was noninferior to dalteparin for the treatment of acute venous thromboembolism (VTE) in patients with cancer. In sensitivity analyses, results were similar with an hierachical outcome of only death, recurrent VTE, and major bleeding (win-ratio, 0.92; 95%-CI, 0.76-1.11), reversed order of the 10 components (win-ratio, 0.87; 95%-CI, 0.73-1.04), or when all-cause death was replaced with VTE-related death or fatal bleeding (win ratio, 0.83; 95%-CI, 0.65-1.06). Table or Figure Upload"

Ischemic stroke • Myocardial Infarction • Oncology • Respiratory Diseases • Venous Thromboembolism

Effectiveness and safety of edoxaban in cancer patients - Results of the DRESDEN NOAC REGISTRY (ISTH 2025) - "Further subset analyses regarding active vs non-active cancer will also be presented. Table or Figure Upload"

Clinical • Atrial Fibrillation • Oncology • Renal Disease • Venous Thromboembolism

Drug-drug Interactions between Immunosuppressants and Direct Oral Anticoagulants in Transplants (ISTH 2025) - "Moderate to strong inhibitors, such as tacrolimus and cyclosporine, can substantially increase DOAC plasma levels, potentially increasing bleeding risk...33 measurements were excluded (e.g. last administration unclear), resulting in 240 measurements considered for analysis: 40 apixaban, 2 dabigatran, 112 edoxaban, and 86 rivaroxaban...Overall, 34 patients (29%) and 52 DOAC levels (22%) exceeded the expected range (Figure). Table or Figure Upload"

Atrial Fibrillation • Cardiovascular • Transplantation • Venous Thromboembolism • CYP3A4

Comparison of inhibitory effects between FXIa inhibitors and DOACs in thrombin generation assay (ISTH 2025) - "Aims This study evaluated the thrombin inhibitory effects of the FXIa inhibitors asundexian and milvexian using an intrinsic pathway thrombin generation assay (TGA) and compared these effects with those of direct oral anticoagulants (DOACs). For apixaban, the peak values at concentrations of 100–5000 ng/mL were 647.5, 570.4, 530.2, 537.4, 495.8, 403.7, and 102.8 nM, respectively; for milvexian, 497.5, 466.1, 370.8, 269.6, 169.8, 48.5 and 11.3 nM. The ranges of peak values for dabigatran, rivaroxaban, apixaban, and edoxaban at 100–1000 ng/mL were 148.1–10.0, 425.3–11.5, 547.2–156.4, and 425.4–42.5 nM, respectively."

Point-of-care urine dipstick for DOAC detection in the emergency setting: a multicenter cohort study (ISTH 2025) - "No other significant differences were observed.At ED arrival, patients were on apixaban, rivaroxaban, edoxaban and dabigatran in 41%, 30%, 20% and 9%, respectively. Mean time from last DOAC assumption to urine sample was 13:39 (standard deviation [SD] 8:17) vs 14:37 (SD 4:57) hours (p=0.573) and to blood sample 12:42 (SD 7:57) vs 17:51 (SD 7:37) hours (p=0.007) in patients with positive vs negative urine and plasma test result, respectively. Table or Figure Upload"

Clinical • Cardiovascular

Reagent variability of APTT prolongation in factor XIa inhibitors of asundexian and milvexian (ISTH 2025) - "For asundexian, the ratios ranged from 1.0 to 2.5, and for milvexian, from 1.0 to 3.8, with ratios increasing proportionally with concentration. At 1000 ng/mL, APTT ranged from 3.1 to 4.1 for dabigatran, 2.0 to 2.9 for rivaroxaban, 1.3 to 1.5 for apixaban, and 1.7 to 2.2 for edoxaban."